Compare BioNano Genomics Inc (BNGO) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Redwire Corporation — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Redwire Corporation trades at $13.57 (market cap $3.38B). The key difference: Redwire Corporation is far larger — about 247.4× BioNano Genomics Inc's market cap, and Redwire Corporation is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | RDW | |
|---|---|---|
Market Cap | $13.66M | $3.38B |
Sector | Health | Technology |
52-Week High | $4.92 | $25.90 |
52-Week Low | $1.06 | $5.06 |
Enterprise Value | $16.26M | $2.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Redwire (RDW) trades at $13.57, up 3.43% with strong technical momentum as the stock approaches its consensus price target of $17.50. The company reported record Q2 2026 revenue of $117.1 million and a $542.1 million backlog, though it continues to post significant net losses with a -57.26% margin. Analyst sentiment remains overwhelmingly positive with 80% buy ratings, while technical indicators show bullish moving averages but overbought RSI conditions.
Redwire presents a growth story fueled by defense contracts and space technology, but faces substantial execution risk given persistent losses and negative cash flow from operations. The stock's upside depends on successful margin improvement and backlog conversion, while downside risk remains from dilution and delayed profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
